Brandon W. Fenn

Partner
Full contact info

Experience

Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical

March 17, 2025

Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.

Read more

Related contacts

Bill Roegge
Partner, New York
Kenneth Krisko
Partner, Reston
Simon Amies
Partner, London
Rita Sobral
Special Counsel, London
Stephanie Parker Palmer
Special Counsel, Reston
Michael Bergmann
Partner, Washington, DC
Brandon W. Fenn
Partner, New York
Eileen Marshall
Partner, Washington, DC
Jeremy Morrison
Partner, Washington, DC
Dr. Matthew Pavao
Partner, Boston
Stella Sarma
Partner, Brussels
Ryan Vann
Partner, Chicago
Natasha Leskovsek
Of Counsel, Washington, DC
Elizabeth Caruso
Associate, New York
Matthew Choy
Associate, New York
Kyle Hess
Associate, New York
Katie Kaufman
Associate, Boston
Edward (Teddy) Nimetz
Associate, New York
Alexandra Paterson
Associate, London
Joseph Perry
Associate, Reston
Dr. Robert E. Powers
Associate, Boston
María Álvarez Requejo Heredero
Associate, Brussels

Related Practices & Industries

Enavate Sciences Co-Leads Normunity’s $75 Million Series B

January 13, 2025

Cooley advised Enavate Sciences, a top investment firm, as the co-lead investor in the $75 million Series B financing round of Normunity, a biotechnology company creating novel anticancer therapies. Lawyers Marc Recht, Brandon Fenn and Barry Kuang led the Cooley team advising Enavate Sciences.

Related contacts

Marc Recht
Partner, Boston
Brandon W. Fenn
Partner, New York
Barry Kuang
Associate, Boston
Liz Gold
Associate, New York
Stephanie Gentile
Partner, New York

Related Practices & Industries

Enavate Sciences Invests in Aviceda Therapeutics $207.5 Million Series C

January 7, 2025

Cooley advised Enavate Sciences, a top investment firm, on its participation in the $207.5 million Series C financing round of Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immunomodulators. Lawyers Marc Recht, Brandon Fenn and Barry Kuang led the Cooley team advising Enavate Sciences.

Related contacts

Marc Recht
Partner, Boston
Brandon W. Fenn
Partner, New York
Barry Kuang
Associate, Boston

Related Practices & Industries

Nuvolo Agrees to Sell to Trane Technologies

October 2, 2023

Cooley advised Nuvolo, a leader in modern, cloud-based connected workplace solutions, on its definitive agreement to be acquired by climate innovator Trane Technologies.

Read more

Related contacts

Kevin Cooper
Partner, New York
Brandon W. Fenn
Partner, New York
Nathan Baum
Special Counsel, New York
Scott D. Rudin
Associate, New York
DeVon Barnett
Associate
Steve Andersen
Associate, New York
Nyron J. Persaud
Partner, New York
Stephanie Gentile
Partner, New York
Megan Browdie
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Michael Tollini
Partner, Washington, DC
Thomas Connors
Partner, Boston
Steve Flores
Partner, Chicago
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Christine Graham
Special Counsel, London
Stella Sarma
Partner, Brussels
Randy Sabett
Special Counsel, Washington, DC
Annie Froehlich
Partner, Washington, DC
Kristopher Kleiner
Special Counsel, Colorado
Karun Ahuja
Special Counsel, Chicago
Anisha Mohin
Associate, New York
Anthony Hajj
Associate, New York
Allison Kutner
Associate, New York
Arthi Naini
Associate, New York
Juan Nascimbene
Associate, London

Related Practices & Industries

Tourmaline Bio Agrees to Merge With Talaris Therapeutics

June 22, 2023

Cooley advised Tourmaline Bio, a late-stage clinical biotechnology company, on its merger agreement with Talaris Therapeutics, including a concurrent private placement.

Read more

Related contacts

Bill Sorabella
Partner, New York
Brandon W. Fenn
Partner, New York
Christine Tse
Associate, New York
Katherine Denby
Special Counsel, Washington, DC

Related Practices & Industries

View more

Admissions and credentials

New York